Tarsus to Acquire Alkeus for $450M Upfront, Adding Phase 3 Stargardt Asset

summarizeSummary

Tarsus Pharmaceuticals will acquire Alkeus Pharmaceuticals for $450 million upfront ($270M cash, $180M stock) plus milestones, gaining a Phase 3 Stargardt disease therapy. The deal expands Tarsus's retina pipeline and is priced at a premium to market.

check_boxKey Events · M&A and Partnerships · TARS

• Acquisition of Alkeus Pharmaceuticals

  Tarsus will acquire Alkeus for $270M cash and $180M in stock upfront, plus up to $350M in regulatory and commercial milestones, and low-single-digit royalties on gildeuretinol sales.

• Stock Consideration Priced at Premium

  The $180M stock component is valued at $61.38 per share, a 5% premium to Tarsus's current $58.50 price, reflecting seller confidence in the deal.

• Adds Phase 3 Stargardt Disease Asset

  Gildeuretinol (ALK-001) is an oral therapy for Stargardt disease, a rare inherited retinal disease with no FDA-approved treatment. Phase 3 NORTHSTAR trial data expected in the second half of 2029.

• Lock-Up and Registration Rights

  Alkeus stockholders receiving upfront stock are subject to a 2-month lock-up, with additional volume-based selling limits for 3 months thereafter. Tarsus will file a resale shelf registration for the shares.

auto_awesomeAnalysis · TARS · Life Sciences

Tarsus is buying Alkeus Pharmaceuticals for $270 million in cash and $180 million in stock, with up to $350 million more in milestones. The deal brings gildeuretinol, a Phase 3 oral therapy for Stargardt disease — a rare, blinding retinal condition with no approved treatment. The stock portion is priced at $61.38, a premium to today's $58.50, signaling seller confidence. This follows last month's iRenix acquisition and builds a retina franchise. The upfront cost is significant but manageable given Tarsus's $2.6 billion market cap and recent XDEMVY sales momentum. Key risk: Phase 3 data not until 2029, so the payoff is years away.